Summary:
A phase II, multicentered, randomized, double-blind, placebo-controlled, parallel-group, efficacy, and safety study of MTAU9937A in patients with prodromal to mild Alzheimer's disease
Qualified Participants Must:
• Patients aged between 50 and 80 years
•
NIA-AA core clinical criteria for probable AD dementia
Qualified Participants May Receive:
Compensation for time and travel